Updated:
PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc. is a Nasdaq-listed biotech developing cell encapsulation therapies for cancer and diabetes.
PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc. is a publicly traded biotechnology company listed on the Nasdaq under the symbol PMCB. The firm focuses on developing its proprietary Cell-in-a-Box technology, which encapsulates engineered living cells in a cellulose-based coating for targeted delivery of therapeutic proteins or enzymes. This platform has been investigated in clinical trials for pancreatic cancer and type 1 diabetes, though no products have received regulatory approval. The company's strategy centers on advancing its two lead programs: a Phase 2b clinical trial for locally advanced, inoperable pancreatic cancer using its CypCyte formulation, and a preclinical type 1 diabetes program. PharmaCyte has also explored partnerships, including a collaboration with Austrianova (Singapore) for manufacturing. Geographic activity is primarily in the United States, with some operations in Europe through its subsidiary. PharmaCyte Biotech is a development-stage entity with no commercial revenue from product sales. As of its latest filings, the company has funded operations through equity offerings and debt financing. Recent activities include continued enrollment in its pancreatic cancer trial and efforts to secure additional capital. The firm employs a small team, with no public disclosure of total professional count. The company's structural differentiator is its cell encapsulation platform, which aims to protect therapeutic cells from immune rejection. However, it remains a pre-revenue biotech firm with no approved products. Its primary mandate is research and development, not capital management or investment.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What is PharmaCyte Biotech's primary technology platform?
PharmaCyte's core platform is Cell-in-a-Box, which encapsulates engineered living cells in a cellulose-based coating for targeted delivery of therapeutic proteins. The technology is designed to protect cells from immune rejection while allowing secretion of drugs. It is being tested in a Phase 2b trial for pancreatic cancer and preclinical studies for type 1 diabetes (per clinicaltrials.gov, NCT identifier reported in company filings).
Is PharmaCyte Biotech a family office or investment firm?
No. PharmaCyte Biotech, Inc. is a publicly traded biotechnology company (Nasdaq: PMCB) focused on drug development. It is not a family office, asset manager, or investment entity. The firm operates as a development-stage biotech with no external investment management mandate.
Has PharmaCyte Biotech generated revenue from product sales?
No. PharmaCyte Biotech has not generated any revenue from commercial product sales. As a development-stage company, it has funded operations through equity and debt offerings. Its financial position is disclosed in SEC filings, which show ongoing operating losses (per SEC, 2024).
What is the current status of PharmaCyte's pancreatic cancer program?
PharmaCyte's pancreatic cancer program uses its CypCyte formulation in a Phase 2b clinical trial for locally advanced, inoperable pancreatic cancer. The trial is ongoing, with enrollment updates provided periodically. No interim efficacy results have been publicly released as of mid-2024 (per clinicaltrials.gov).
Who are the key executives at PharmaCyte Biotech?
PharmaCyte Biotech's leadership has included individuals from biotech and pharmaceutical backgrounds. The company's CEO and board members are disclosed in SEC filings and corporate announcements. However, without current primary source access, specific named individuals cannot be confirmed here. Investors should refer to the firm's latest proxy statement.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: